These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 36096178)
1. Different phenotypic outcome due to site-specific phosphorylation in the cancer-associated NQO1 enzyme studied by phosphomimetic mutations. Pacheco-Garcia JL; Anoz-Carbonell E; Loginov DS; Vankova P; Salido E; Man P; Medina M; Palomino-Morales R; Pey AL Arch Biochem Biophys; 2022 Oct; 729():109392. PubMed ID: 36096178 [TBL] [Abstract][Full Text] [Related]
2. Phosphorylation compromises FAD binding and intracellular stability of wild-type and cancer-associated NQO1: Insights into flavo-proteome stability. Medina-Carmona E; Rizzuti B; Martín-Escolano R; Pacheco-García JL; Mesa-Torres N; Neira JL; Guzzi R; Pey AL Int J Biol Macromol; 2019 Mar; 125():1275-1288. PubMed ID: 30243998 [TBL] [Abstract][Full Text] [Related]
3. Structural basis of the pleiotropic and specific phenotypic consequences of missense mutations in the multifunctional NAD(P)H:quinone oxidoreductase 1 and their pharmacological rescue. Pacheco-Garcia JL; Anoz-Carbonell E; Vankova P; Kannan A; Palomino-Morales R; Mesa-Torres N; Salido E; Man P; Medina M; Naganathan AN; Pey AL Redox Biol; 2021 Oct; 46():102112. PubMed ID: 34537677 [TBL] [Abstract][Full Text] [Related]
4. Thermodynamics of cooperative binding of FAD to human NQO1: Implications to understanding cofactor-dependent function and stability of the flavoproteome. Clavería-Gimeno R; Velazquez-Campoy A; Pey AL Arch Biochem Biophys; 2017 Dec; 636():17-27. PubMed ID: 29100982 [TBL] [Abstract][Full Text] [Related]
5. A single evolutionarily divergent mutation determines the different FAD-binding affinities of human and rat NQO1 due to site-specific phosphorylation. Pacheco-Garcia JL; Loginov D; Rizzuti B; Vankova P; Neira JL; Kavan D; Mesa-Torres N; Guzzi R; Man P; Pey AL FEBS Lett; 2022 Jan; 596(1):29-41. PubMed ID: 34817874 [TBL] [Abstract][Full Text] [Related]
6. Site-to-site interdomain communication may mediate different loss-of-function mechanisms in a cancer-associated NQO1 polymorphism. Medina-Carmona E; Neira JL; Salido E; Fuchs JE; Palomino-Morales R; Timson DJ; Pey AL Sci Rep; 2017 Mar; 7():44532. PubMed ID: 28291250 [TBL] [Abstract][Full Text] [Related]
7. A mutually inhibitory feedback loop between the 20S proteasome and its regulator, NQO1. Moscovitz O; Tsvetkov P; Hazan N; Michaelevski I; Keisar H; Ben-Nissan G; Shaul Y; Sharon M Mol Cell; 2012 Jul; 47(1):76-86. PubMed ID: 22793692 [TBL] [Abstract][Full Text] [Related]
8. NAD(P)H quinone oxidoreductase (NQO1): an enzyme which needs just enough mobility, in just the right places. Pey AL; Megarity CF; Timson DJ Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30518535 [TBL] [Abstract][Full Text] [Related]
9. Anion-specific interaction with human NQO1 inhibits flavin binding. Pey AL Int J Biol Macromol; 2019 Apr; 126():1223-1233. PubMed ID: 30615965 [TBL] [Abstract][Full Text] [Related]
10. NQO1: A target for the treatment of cancer and neurological diseases, and a model to understand loss of function disease mechanisms. Beaver SK; Mesa-Torres N; Pey AL; Timson DJ Biochim Biophys Acta Proteins Proteom; 2019; 1867(7-8):663-676. PubMed ID: 31091472 [TBL] [Abstract][Full Text] [Related]
11. Conformational dynamics is key to understanding loss-of-function of NQO1 cancer-associated polymorphisms and its correction by pharmacological ligands. Medina-Carmona E; Palomino-Morales RJ; Fuchs JE; Padín-Gonzalez E; Mesa-Torres N; Salido E; Timson DJ; Pey AL Sci Rep; 2016 Feb; 6():20331. PubMed ID: 26838129 [TBL] [Abstract][Full Text] [Related]
12. NAD(P)H:quinone oxidoreductase 1 (NQO1) competes with 20S proteasome for binding with C/EBPα leading to its stabilization and protection against radiation-induced myeloproliferative disease. Xu J; Jaiswal AK J Biol Chem; 2012 Dec; 287(50):41608-18. PubMed ID: 23086932 [TBL] [Abstract][Full Text] [Related]
13. A mechanism for cancer-associated inactivation of NQO1 due to P187S and its reactivation by the consensus mutation H80R. Muñoz IG; Morel B; Medina-Carmona E; Pey AL FEBS Lett; 2017 Sep; 591(18):2826-2835. PubMed ID: 28771686 [TBL] [Abstract][Full Text] [Related]
14. Counterintuitive structural and functional effects due to naturally occurring mutations targeting the active site of the disease-associated NQO1 enzyme. Pacheco-García JL; Anoz-Carbonell E; Loginov DS; Kavan D; Salido E; Man P; Medina M; Pey AL FEBS J; 2023 Apr; 290(7):1855-1873. PubMed ID: 36378023 [TBL] [Abstract][Full Text] [Related]
15. NAD(P)H quinone-oxydoreductase 1 protects eukaryotic translation initiation factor 4GI from degradation by the proteasome. Alard A; Fabre B; Anesia R; Marboeuf C; Pierre P; Susini C; Bousquet C; Pyronnet S Mol Cell Biol; 2010 Feb; 30(4):1097-105. PubMed ID: 20028737 [TBL] [Abstract][Full Text] [Related]
16. Biophysical and functional perturbation analyses at cancer-associated P187 and K240 sites of the multifunctional NADP(H):quinone oxidoreductase 1. Pey AL Int J Biol Macromol; 2018 Oct; 118(Pt B):1912-1923. PubMed ID: 30009918 [TBL] [Abstract][Full Text] [Related]
17. A Dynamic Core in Human NQO1 Controls the Functional and Stability Effects of Ligand Binding and Their Communication across the Enzyme Dimer. Vankova P; Salido E; Timson DJ; Man P; Pey AL Biomolecules; 2019 Nov; 9(11):. PubMed ID: 31726777 [TBL] [Abstract][Full Text] [Related]
18. Akt Phosphorylates NQO1 and Triggers its Degradation, Abolishing Its Antioxidative Activities in Parkinson's Disease. Luo S; Kang SS; Wang ZH; Liu X; Day JX; Wu Z; Peng J; Xiang D; Springer W; Ye K J Neurosci; 2019 Sep; 39(37):7291-7305. PubMed ID: 31358653 [TBL] [Abstract][Full Text] [Related]